泰坦制药公司（纳斯达克股票代码：TTNP）预计空头利率将大幅下降

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Rating) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 39,700 shares, a decline of 30.0% from the February 13th total of 56,700 shares. Based on an average daily trading volume, of 39,600 shares, the days-to-cover ratio is currently 1.0 days.

Insider Buying and Selling

In other news, CEO David E. Lazar purchased 37,500 shares of the stock in a transaction on Tuesday, January 24th. The stock was bought at an average price of $0.97 per share, with a total value of $36,375.00. Following the transaction, the chief executive officer now owns 3,368,902 shares in the company, valued at approximately $3,267,834.94. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Titan Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Truist Financial Corp acquired a new stake in Titan Pharmaceuticals in the third quarter valued at about $675,000. Renaissance Technologies LLC increased its stake in shares of Titan Pharmaceuticals by 559.3% during the 2nd quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company's stock worth $135,000 after purchasing an additional 204,200 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Titan Pharmaceuticals during the 2nd quarter worth approximately $35,000. Millennium Management LLC increased its stake in shares of Titan Pharmaceuticals by 516.8% during the 2nd quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company's stock worth $35,000 after purchasing an additional 52,874 shares in the last quarter. Finally, State Street Corp purchased a new stake in Titan Pharmaceuticals in the 3rd quarter worth approximately $41,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

Titan Pharmaceuticals Price Performance

NASDAQ:TTNP remained flat at $0.86 during trading hours on Friday. The company's stock had a trading volume of 11,109 shares, compared to its average volume of 14,410. The stock has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.01. Titan Pharmaceuticals has a one year low of $0.35 and a one year high of $1.59.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a research report on Sunday. They issued a "sell" rating for the company.

About Titan Pharmaceuticals

(Get Rating)

Titan Pharmaceuticals, Inc engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R.

See Also

• Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
• What the SVB Financial Collapse Means for U.S. Banks
• MarketBeat Week in Review – 3/6 – 3/10
• 2 Offshore Drilling Stocks Set to Extract Big Profits
• Three Staples Stocks With Double-Digit Upside Ahead
• Can Investors Trust Consumers to Lift American Outdoor Brands?

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.